{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:14:28Z","timestamp":1788509668837,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003803","name":"The University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["IAA 2021 UCL MR\/X502984\/1"],"award-info":[{"award-number":["IAA 2021 UCL MR\/X502984\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005041","name":"Universit\u00e9 Catholique de Louvain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"UCL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104301","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:04:41Z","timestamp":1777417481000},"page":"104301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Probing surfactant protein B fragments as endogenous RNA carriers for pulmonary delivery"],"prefix":"10.1016","volume":"115","author":[{"given":"Michael Y.T.","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Goldbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1837-1323","authenticated-orcid":false,"given":"Siti Ardyanti Rohadatul","family":"Aisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Cipollone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-010X","authenticated-orcid":false,"given":"Jenny K.W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2026.104301_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1124\/molpharm.124.000895","article-title":"The growing class of novel RNAi therapeutics","volume":"106","author":"Traber","year":"2024","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104301_bib0002","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.xphs.2026.104301_bib0003","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tips.2020.04.007","article-title":"Therapeutic RNA strategies for chronic obstructive pulmonary disease","volume":"41","author":"Mei","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104301_bib0004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-021-01338-2","article-title":"RNA-based therapies: a cog in the wheel of lung cancer defense","volume":"20","author":"Khan","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.xphs.2026.104301_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1281538","article-title":"Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions","volume":"14","author":"Man","year":"2023","journal-title":"Front Genet"},{"issue":"8","key":"10.1016\/j.xphs.2026.104301_bib0006","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2026.104301_bib0007","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.xphs.2026.104301_bib0008","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","article-title":"Combinatorial development of nebulized mRNA delivery formulations for the lungs","volume":"19","author":"Jiang","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.xphs.2026.104301_bib0009","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jconrel.2022.09.021","article-title":"Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery","volume":"351","author":"Zimmermann","year":"2022","journal-title":"J Control Release"},{"issue":"49","key":"10.1016\/j.xphs.2026.104301_bib0010","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/j.xphs.2026.104301_bib0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"8","key":"10.1016\/j.xphs.2026.104301_bib0012","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.xphs.2019.03.029","article-title":"Establishment of an evaluation method for gene silencing by serial pulmonary administration of siRNA and pDNA powders: naked siRNA inhalation powder suppresses luciferase gene expression in the lung","volume":"108","author":"Ito","year":"2019","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104301_bib0013","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.antiviral.2007.11.009","article-title":"Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)","volume":"77","author":"DeVincenzo","year":"2008","journal-title":"Antiviral Res"},{"issue":"19","key":"10.1016\/j.xphs.2026.104301_bib0014","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.xphs.2026.104301_bib0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.201003-0422OC","article-title":"RNA interference therapy in lung transplant patients infected with respiratory syncytial virus","volume":"183","author":"Zamora","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.xphs.2026.104301_bib0016","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","article-title":"ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients","volume":"35","author":"Gottlieb","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.xphs.2026.104301_bib0017","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/acs.molpharmaceut.7b00725","article-title":"From pulmonary surfactant, synthetic KL4 peptide as effective siRNA delivery vector for pulmonary delivery","volume":"14","author":"Qiu","year":"2017","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104301_bib0018","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bpj.2024.04.021","article-title":"The biophysical function of pulmonary surfactant","volume":"123","author":"Hall","year":"2024","journal-title":"Biophys J"},{"issue":"5","key":"10.1016\/j.xphs.2026.104301_bib0019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3345\/kjp.2018.07185","article-title":"Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future","volume":"62","author":"Jeon","year":"2019","journal-title":"Korean J Pediatr"},{"issue":"9","key":"10.1016\/j.xphs.2026.104301_bib0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00249-012-0850-4","article-title":"Effects of the lung surfactant protein B construct mini-B on lipid bilayer order and topography","volume":"41","author":"Palleboina","year":"2012","journal-title":"Eur Biophys J"},{"issue":"3","key":"10.1016\/j.xphs.2026.104301_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000451076","article-title":"Design of surfactant protein B peptide mimics based on the saposin fold for synthetic lung surfactants","volume":"1","author":"Walther","year":"2016","journal-title":"Biomed Hub"},{"issue":"5","key":"10.1016\/j.xphs.2026.104301_bib0022","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1039\/D4CB00295D","article-title":"Peptides: potential delivery systems for mRNA","volume":"6","author":"Liang","year":"2025","journal-title":"RSC Chem Biol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104301_bib0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1089\/nat.2020.0855","article-title":"Modification of KL4 peptide revealed the importance of alpha-helical structure for efficient siRNA delivery","volume":"31","author":"Qiu","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.xphs.2026.104301_bib0024","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","article-title":"Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide","volume":"314","author":"Qiu","year":"2019","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2026.104301_bib0025","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1021\/acs.molpharmaceut.0c01242","article-title":"Optimization of PEGylated KL4 peptide for siRNA delivery with improved pulmonary tolerance","volume":"18","author":"Qiu","year":"2021","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2026.104301_bib0026","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s13346-024-01773-w","article-title":"Robust peptide\/RNA complexes prepared with microfluidic mixing for pulmonary delivery by nebulisation","volume":"15","author":"Ma","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.xphs.2026.104301_bib0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-62703-311-4_5","article-title":"Western blot evaluation of siRNA delivery by pH-responsive peptides","volume":"986","author":"Liang","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104301_bib0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/nat.2019.0804","article-title":"Endocytosis controls siRNA efficiency: implications for siRNA delivery vehicle design and cell-specific targeting","volume":"30","author":"Vocelle","year":"2020","journal-title":"Nucleic Acid Ther"},{"issue":"6","key":"10.1016\/j.xphs.2026.104301_bib0029","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1399-3011.2005.00300.x","article-title":"The role of charged amphipathic helices in the structure and function of surfactant protein B","volume":"66","author":"Waring","year":"2005","journal-title":"J Pept Res"},{"issue":"1","key":"10.1016\/j.xphs.2026.104301_bib0030","doi-asserted-by":"crossref","first-page":"e8672","DOI":"10.1371\/journal.pone.0008672","article-title":"Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs","volume":"5","author":"Walther","year":"2010","journal-title":"PLoS One"},{"issue":"48","key":"10.1016\/j.xphs.2026.104301_bib0031","doi-asserted-by":"crossref","first-page":"15187","DOI":"10.1021\/bi0481895","article-title":"NMR structures of the C-terminal segment of surfactant protein B in detergent micelles and hexafluoro-2-propanol","volume":"43","author":"Booth","year":"2004","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.xphs.2026.104301_bib0032","doi-asserted-by":"crossref","first-page":"L335","DOI":"10.1152\/ajplung.00190.2009","article-title":"Functional importance of the NH2-terminal insertion sequence of lung surfactant protein B","volume":"298","author":"Frey","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"9","key":"10.1016\/j.xphs.2026.104301_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072821","article-title":"Role of the N-terminal seven residues of surfactant protein B (SP-B)","volume":"8","author":"Sharifahmadian","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.xphs.2026.104301_bib0034","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/j.bbamem.2016.09.014","article-title":"Stability of an amphipathic helix-hairpin surfactant peptide in liposomes","volume":"1858","author":"Waring","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"30","key":"10.1016\/j.xphs.2026.104301_bib0035","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.1021\/bi016077x","article-title":"NMR structure of lung surfactant peptide SP-B(11-25)","volume":"41","author":"Kurutz","year":"2002","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.xphs.2026.104301_bib0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/mt.2008.215","article-title":"A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells","volume":"17","author":"Crombez","year":"2009","journal-title":"Mol Ther"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104301_bib0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2016.05.030","article-title":"Optimisation of vectorisation property: a comparative study for a secondary amphipathic peptide","volume":"509","author":"Konate","year":"2016","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104301_bib0038","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jconrel.2011.11.024","article-title":"Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways","volume":"158","author":"Lam","year":"2012","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2026.104301_bib0039","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1021\/acs.bioconjchem.8b00776","article-title":"Peptide-based nanoparticles to rapidly and efficiently \"wrap 'n roll\" siRNA into cells","volume":"30","author":"Konate","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.xphs.2026.104301_bib0040","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jconrel.2020.10.049","article-title":"Macropinocytosis as a cell entry route for peptide-functionalized and bystander nanoparticles","volume":"329","author":"Li","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2026.104301_bib0041","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12935-019-0973-0","article-title":"Extracellular and macropinocytosis internalized ATP work together to induce epithelial-mesenchymal transition and other early metastatic activities in lung cancer","volume":"19","author":"Cao","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"10","key":"10.1016\/j.xphs.2026.104301_bib0042","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1021\/nn4027382","article-title":"Rational design of a biomimetic cell penetrating peptide library","volume":"7","author":"Karagiannis","year":"2013","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.xphs.2026.104301_bib0043","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/membranes10080177","article-title":"Macropinocytosis in different cell types: similarities and differences","volume":"10","author":"Lin","year":"2020","journal-title":"Membranes (Basel)"},{"issue":"9","key":"10.1016\/j.xphs.2026.104301_bib0044","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1016\/j.ymthe.2024.06.038","article-title":"Discovery of a novel inhibitor of macropinocytosis with antiviral activity","volume":"32","author":"Porebski","year":"2024","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.xphs.2026.104301_bib0045","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/IAI.67.8.4161-4170.1999","article-title":"Infection of primary human bronchial epithelial cells by Haemophilus influenzae: macropinocytosis as a mechanism of airway epithelial cell entry","volume":"67","author":"Ketterer","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.xphs.2026.104301_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.067","article-title":"Surfactant protein B-derived peptides as endosomal escape enhancers for pulmonary delivery of siRNA","volume":"381","author":"Herman","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2026.104301_bib0047","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.actbio.2018.08.012","article-title":"Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy","volume":"78","author":"Merckx","year":"2018","journal-title":"Acta Biomater"},{"issue":"5","key":"10.1016\/j.xphs.2026.104301_bib0048","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.1021\/acsnano.0c04489","article-title":"Surfactant protein B promotes cytosolic SiRNA delivery by adopting a virus-like mechanism of action","volume":"15","author":"Guagliardo","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.xphs.2026.104301_bib0049","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2022.02.010","article-title":"Current state of the art in peptide-based gene delivery","volume":"343","author":"Hadianamrei","year":"2022","journal-title":"J Control Release"},{"issue":"Pt 1","key":"10.1016\/j.xphs.2026.104301_bib0050","article-title":"Peptide-based non-viral gene delivery: a comprehensive review of the advances and challenges","volume":"266","author":"Xiang","year":"2024","journal-title":"Int J Biol Macromol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:36:04Z","timestamp":1788507364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001504"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104301","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Probing surfactant protein B fragments as endogenous RNA carriers for pulmonary delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104301"}}